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OBJECTIVE: To explore the use of b-lactoglobulin polymerized using microbial transglutaminase and heating to
identify whether protein polymerization could reduce in vivo allergenicity and maintain in vitro and ex vivo
immunoreactivity for use in tolerance-induction protocols.
METHODS: Based on previous protocols applied in mice and children, we performed in vivo challenges (using a skin
prick test) with native and polymerized b-lactoglobulin in adult patients with an IgE-mediated allergy to b-
lactoglobulin. In vitro humoral immunoreactivity was analyzed using immunoblotting. Cell-mediated immunor-
eactivity was analyzed using ex vivo challenges with native and polymerized b-lactoglobulin and monitored by
leukocyte adherence inhibition tests.
RESULTS: The skin tests demonstrated that there was a significant reduction in immediate cutaneous reactivity after
polymerization. Polymerization did not decrease the immunoblotting detection of s-IgE specific to b-lactoglobulin.
Cell-mediated immunoreactivity, as assessed by ex vivo challenges and leukocyte adherence inhibition tests, did not
exhibit significant differences between leukocytes challenged with native versus polymerized b-lactoglobulin.
CONCLUSIONS: The polymerization of b-lactoglobulin decreased in vivo allergenicity and did not decrease in vitro
humoral or ex vivo cell-mediated immunoreactivity. Therefore, we conclude that inducing polymerization using
transglutaminase represents a promising technique to produce suitable molecules for the purpose of designing oral/
sublingual tolerance induction protocols for the treatment of allergies.
KEYWORDS: Beta-lactoglobulin; Milk Hypersensitivity; Leukocyte Adherence Inhibition Test; Polymerization;
Immune Tolerancez.
Olivier CE, Lima RP, Pinto DG, Santos RA, Silva GK, Lorena SL, et al. In search of a tolerance-induction strategy for cow’smilk allergies: significant reductionof
beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization. Clinics. 2012;67(10):1171-1179.
Received for publication on March 24, 2012; First review completed on April 24, 2012; Accepted for publication on June 19, 2012
E-mail: zollner@unicamp.br
Tel.: 55 19 3289 3709
INTRODUCTION
The primary strategy currently used to manage cow’s
milk allergies is to diagnose the offending protein (whey
proteins, cheese caseins or both) and prescribe its dietary
elimination (1-3). Nevertheless, avoidance strategies may
also contribute to a loss of tolerance (4). Oral tolerance
induction protocols using whole cow’s milk have been
described (5,6). However, the use of a natural extract of an
allergen may elicit allergic reactions, thereby limiting the
progress of desensitization. Modified allergens (allergoids)
have been used in desensitization protocols to minimize the
allergic reactions produced by the native allergen (7). Less
allergenic immuno-equivalent proteins may be obtained, for
example, using recombinant DNA technology (8), but this
method is laborious and expensive. More accessible
approaches, including extensive baking, have been used
for milk tolerance induction based on the assumption that
the destruction of conformational epitopes yields a safer
protein for oral administration (9). However, this type of
physical denaturation may also induce difficult-to-control
chemical modifications in the allergen, making the char-
acterization of the resultant allergen almost impossible
while simultaneously destroying the linear epitopes neces-
sary to prime tolerance induction (10). The rationale for
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performing safe and efficient oral tolerance induction
protocols ideally includes the use of a protein that is
immunogenic (harboring all relevant T cell epitopes) but
less allergenic (eliciting weaker clinical reactions) (11). The
allergenicity of a modified antigen may be evaluated using
in vivo challenge tests (cutaneous or oral) and/or ex vivo
challenge tests, such as the basophil degranulation assay.
The extent of the allergen-elicited cell-mediated immunor-
eactivity responsible for priming the subsequent immune
response and/or tolerance may be analyzed prior to
treatment using T cell proliferation assays (12) or after
treatment by detecting markers of immune tolerance from
cultured PBMCs or searching for inducible Tregs expressing
IL-10 and TGF-b (13). As a model for this study, we
employed enzymatic polymerization, a process that is
widely used to produce industrial foods. The use of
biotechnology to modify the physical properties of dairy
products is currently practiced and can alter the allergeni-
city of native proteins, thereby resulting in the creation of
new and troublesome allergens or less allergenic (hypoal-
lergenic) products (14). Among bovine whey proteins, b-
lactoglobulin (b-Lg) is a prevalent allergen, as demonstrated
by oral challenges, skin scratch tests and skin prick tests
(SPTs) (15). Because polymerization enzymes, such as
microbial transglutaminase (TG), are applied to decrease
syneresis, polymerized b-Lg is found in industrialized dairy
products, such as curd cheese and yogurt. TG catalyzes
acyl-transfer reactions between the gamma-carboxyamide
groups of glutamine residues and the epsilon-amino group
of lysine, thereby causing the inter- or intramolecular
crosslinking of proteins (16). Previous studies in mice have
demonstrated that the polymerization of b-Lg by TG in the
presence of cysteine may reduce b-Lg antigenicity before
and after digestion (17,18). SPTs have also indicated that
polymerized b-Lg may be less allergenic than native b-Lg in
children with an IgE-mediated cow’s milk allergy (19).
However, ex vivo cell-mediated immunoreactivity to poly-
merized b-Lg has not yet been studied in humans. Seeking
an immunogenic but less allergenic molecule for use in
desensitization protocols and in accordance with the
directive of the FAO/WHO decision tree for analyzing the
allergenicity of foods derived from biotechnological pro-
cesses (20), we examined the allergenicity and immunor-
eactivity of native and polymerized b-Lg in adults with and
without a confirmed diagnosis of an IgE-mediated allergy to
b-Lg. The FAO/WHO directive recommends performing
the diagnosis of a specific IgE-mediated allergy following
SPTs using the native and bioprocessed proteins in people
with proven allergies to the native protein. Because the
detection of a specific IgE using SPT or ImmunoCAP assays
is associated with certain pitfalls (21), we also performed
confirmatory SDS-PAGE immunoblots to improve analyti-
cal sensitivity and detect false-negative or false-positive
results (22). This analysis was conducted in accordance with
the GRADE approach (grades of recommendation, assess-
ment development and evaluation) for grading the quality
of evidence of diagnostic tests (23). Therefore, as a
secondary endpoint, we assessed the sensitivity of the
ImmunoCAP and SPT assays for detecting specific IgE
antibodies against b-Lg in patients who exhibited specific
IgE sensitization, as confirmed by SDS-PAGE immunoblot-
ting. Ex vivo cell-mediated immunoreactivity for b-Lg has
previously been evaluated with the leukocyte migration
inhibition test (24). We used an equivalent but technically
simpler assay to assess b-Lg cell-mediated immunoreactiv-
ity: the leukocyte adherence inhibition test (LAIT) (25-28).
MATERIALS AND METHODS
Ethics Statements
This study was submitted to and approved by the
Institutional Research Ethics Board and was registered in
the Brazilian National Ethics Research System (SISNEP 409/
2008). In accordance with the Helsinki Declaration, signed
consent forms were obtained from all subjects.
Study design and subjects
This descriptive case-control study was designed to
examine the following parameters: A) the in vivo allergeni-
city of native b-Lg and transglutaminase/cysteine-polymer-
ized b-Lg (TgPolb-Lg) in symptomatic adult patients
exhibiting specific IgE antibodies against b-Lg (bs-IgE); B)
the in vitro humoral immunoreactivity of native b-Lg and
heated polymerized b-Lg (HtPolb-Lg) in symptomatic adult
patients exhibiting bs-IgE, as diagnosed by SDS-PAGE
immunoblotting, SPT and ImmunoCAP assays; and C) the
ex vivo cell-mediated immunoreactivity of b-Lg and TgPolb-
Lg, independent of patient bs-IgE status. The participants
were divided into three groups according to their clinical
presentation and analytical results. The first group (group
A) included 45 patients (17 males; mean age: 46.2 years, SD:
12.2 years) with convincing clinical histories of reproducible
adverse reactions to bovine milk. All subjects exhibited bs-
IgE detectable by SDS-PAGE immunoblotting. The second
group (group B) was used as a control for the immunoblot-
ting analysis performed in the first group and included 20
individuals selected based on an evident tolerance to cow’s
milk, an absence of bs-IgE by ImmunoCAP assay and SPT
non-reactivity to b-Lg or TgPolb-Lg (6 males; mean age: 21.9
years, SD: 17.6 years). The third group (group C) included
49 subjects with atopic respiratory and/or dermatological
diseases (19 males; mean age: 28.7 years, SD: 20.6 years)
regardless of bs-IgE status. This group was used to compare
the ex vivo cell-mediated immunoreactivity between b-Lg
and TgPolb-Lg by comparing the mean ex vivo antigenic
challenge results determined using the leukocyte adherence
inhibition test (LAIT).
Allergens, antibodies and reagents
Chromatographically purified b-Lg (.95% pure) was
provided by Davisco Foods, Inc. (Le Sueur, USA). A goat
polyclonal secondary antibody to human IgE–epsilon chain
(ab9159) and peroxidase (HRP)-conjugated rabbit polyclo-
nal secondary antibody to goat IgG (ab6741) were acquired
from Abcam, Inc. (Cambridge, MA, USA). A commercial
preparation of transglutaminase from Streptoverticillium
mobaraense (ActivaH) containing 99% maltodextrin and 1%
transglutaminase (TG) with a declared activity of 100 U/g
was donated by Ajinomoto Co. (Tokyo, Japan). Cysteine,
sodium dodecyl sulfate (SDS) and 3,3’-diaminobenzidine
tetrahydrochloride (DAB) were obtained from Sigma-
Aldrich Chemie GmbH (Steinheim, Germany). Tween-20
and b-mercaptoethanol were obtained from Merck KgaA
(Darmstadt, Germany).
b-lactoglobulin polymerization
For immunoblotting, b-Lg was polymerized by heating
(see Reducing SDS-PAGE section) to stimulate the forma-
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tion of tetramers (HtPolb-Lg) because the high-molecular
weight polymers generated by transglutaminase activity did
not penetrate the SDS-PAGE gel.
For skin tests, cysteine/transglutaminase b-Lg polymer-
ization was performed as described previously (18).
Preparation of solutions for skin tests
To standardize skin tests with respect to the conditions of
previous studies (2), b-Lg and TgPolb-Lg skin solutions
were diluted to a concentration of 10,000 PNU/mL.
Nitrogen levels were quantified by Kjeldahl’s method
(AOAC 991.22), which indicated that each gram of
lyophilized b-Lg contained 14.4 g of nitrogen and each
gram of lyophilized TgPolb-Lg contained 11.1 g of nitrogen.
For the skin tests, b-Lg, TgPolb-Lg and the control
substances were solubilized at a pH of 7.0 and diluted to
their final concentrations using a 20% w/v glycerol/saline
solution (20% GS). The b-Lg solution was diluted to a
concentration of 0.7 mg/mL using 20% GS, and the TgPolb-
Lg solution was diluted to a final concentration of 0.9 mg/
mL using 20% GS. The TG and cysteine skin reactivities
were tested simultaneously. The TG solution for the skin
tests was diluted to a concentration of 0.2 mg/mL using
20% GS, and the cysteine solution for the skin tests was
diluted to 0.3 mg/mL using 20% GS. Histamine (1 mg/mL
in 20% GS) was used as a positive control, and the negative-
control solution was 20% GS.
Skin test methodology
Skin tests were performed on the volar aspect of the
patient’s forearms after withholding antihistamines for at
least 10 days. Skin prick tests (SPTs) were performed using a
disposable sterile acrylic needle consisting of a 1-mm lancet
attached to a blunt base (PunctorH, Alko do Brasil Ltda, Rio
de Janeiro, Brazil). The needle was introduced at a 90˚angle
to the skin through an allergen solution droplet, removed
after 1 second and discarded. The final reading was
performed 15 minutes later, and the wheal’s greatest
diameter and its perpendicular length at that point were
measured to estimate the mean wheal diameter (MWD) (29).
Because there was no reaction to the negative control, a
MWD $3 mm was considered significant for sensitization.
The samples were analyzed by SDS-PAGE under redu-
cing conditions using a Mini Protean Tetra Cell apparatus
(Bio-Rad, CA, USA) and 5%T/20%C gel gradients (30).
Purified b-Lg samples (5 mg/mL) were prepared in a buffer
containing 2% SDS and 5% b-mercaptoethanol and then
heated for 10 min at 96 C˚. An aliquot of 5 mL, which was
equivalent to 25 mg of protein, was applied to each lane. A
10-170 kDa molecular mass pre-stained protein ladder
(PageRulerH, Fermentas, Hanover, MD, USA) was used to
identify approximate molecular weights.
Following electrophoresis, the proteins were electro-
blotted onto 0.45-mm pore-size nitrocellulose membranes
(Bio-Rad) using a Mini Trans-Blot Cell apparatus (Bio-Rad).
Membranes were incubated overnight at 4 C˚ with gentle
agitation in 3 mL phosphate-buffered saline (PBS), pH 7.0,
containing 3 mL of the individual patient’s serum, followed
by three washes in PBST (PBS containing 0.05% Tween-20).
The membranes were incubated under gentle agitation for
2 hours in polyclonal goat IgG anti-human IgE (15 mg in
3 mL PBS), washed three times with PBST and incubated
with horseradish peroxidase (HRP)-conjugated rabbit anti-
goat IgG (30 mg in 3 mL PBS) for 2 hours. After three washes
with PBST, HRP activity was stimulated by incubating the
membranes in 10 mL PBS containing 0.05% DAB followed
by the addition of 50 mL developing solution (CoCl2.6H2O
plus NiSO4) and 20 mL of hydrogen peroxide (H2O2) (31).
When impregnation and color development were complete,
the membranes were washed in distilled water and subse-
quently dried. Images of the membranes were digitalized,
and the relative densitometry of the bands was analyzed
using ImageJ software (Windows version 1.44 of NIH ImageJ,
http://rsb.info.nih.gov/ij/index.html) by measuring the
average optical density (OD). Adjusted optical density
(AOD) was calculated following background correction by
subtracting the average OD from a user-defined area within
the image from the average OD of a similar area defined
around the measured bands (32).
Polymerization of b-Lg via heating created 72-kDa b-Lg
tetramers (HtPolb-Lg) exhibiting an electrophoretic mobility
similar to BSA (66.7 kDa) (33). Although the b-Lg samples
were purified, we performed parallel in vitro serum
competition assays with BSA (1 mg/mL) to rule out the
possibility of BSA interference in the assay.
The concentrations of serum IgE antibodies specific for b-
Lg were measured by ImmunoCAP assays (Pharmacia,
Uppsala, Sweden), and the results were expressed in kU/L.
A concentration greater than 0.35 kU/L was considered
significant for sensitization (34).
Leukocyte adherence inhibition test
Leukocytes from heparin-treated blood samples drawn by
venipuncture from the forearm were separated from fresh
blood by sedimentation at 37 C˚ for one hour. Aliquots of 100
mL of plasma were incubated with 10 mL of each antigen
extract (the same solutions used in the skin tests: b-Lg at
0.7 mg/mL in 20% GS and TgPolb-Lg at 0.9 mg/mL in 20%
GS) for 30 minutes under gentle agitation (200 rpm) at 37 C˚.
Plasma without antigens was used as a control. After
incubation, the plasma was placed into a standard Neubauer
hemocytometer counting chamber with a plain, non-metallic
glass surface and left to stand for 2 hours at 37 C˚ in a
humidified atmosphere to allow leukocytes to adhere to the
glass. The leukocytes were then counted, the coverslip was
gently removed, and the chamber was washed by immersion
in a beaker with PBS at 37 C˚. A drop of PBS was subsequently
added to the hemocytometer chamber, and a clean coverslip
was placed over it. The remaining cells were counted in the
same squares examined previously. The percentage of cell
adherence (cell number after washing/cell number before
washing) was calculated, and leukocyte adherence inhibition
(LAI) was estimated based on the ratio between the percentage
of adherent cells from the challenged groups versus the
control groups: LAI = [1-(% adherent cells of challenged
sample/% adherent cells of control sample)]x100.
Statistical analyses
Statistical analyses and graphs were produced using
GraphPad Prism software (version 5.0; GraphPad Software,
Inc., San Diego, CA, USA). The data are reported as
arithmetic means with 95% confidence intervals (CI) and
standard deviations (SD). Differences in the means of matched
samples were assessed by paired t-tests. Contingency tables
analyzed by chi-square and Fisher’s exact tests were used to
compare the categorical diagnostic performance between
assays. Spearman correlations were used to analyze the
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LAIT results between b-Lg and TgPolb-Lg. For all analyses, a
p-value of less than 0.05 was considered significant.
RESULTS
Group A: ImmunoCAP s-IgE
The mean level of IgE antibodies specific for b-Lg was
1.5 kU L-1 (CI: 0.5 to 2.4; SD: 3.2 kU/L). Specific IgE
antibodies were detected using ImmunoCAP assays in 19
patients (sensitivity = 42.2 %). The test results are presented
in Table 1.
Group A: Skin Prick Test
The test results are presented in Table 1. The mean MWD
for histamine (positive control) obtained by SPT was 6.8 mm
(CI: 6.2 to 7.3; SD: 1.8 mm). b-Lg was reactive in SPTs in 26
patients (sensitivity = 57.7%). The mean MWD for b-Lg
obtained by SPT was 2.6 mm (CI: 1.9 to 3.4; SD: 2.5 mm).
TgPolb-Lg was reactive in SPTs in 19 patients (sensitiv-
ity = 42.2%). The mean MWD for TgPolb-Lg obtained by SPT
was 1.6 mm (CI: 1.0 to 2.2; SD: 2.0 mm). The mean
difference between the paired MWD means for b-Lg and
TgPolb-Lg was 1.0 (p= 0.0075). There was no skin reactivity
observed against TG, cysteine or the negative control
solution in any patient (results not shown).
Comparison of categorical performance between
assays
Analysis of the contingency table between the Im-
munoCAP (19 positives) and SPT assays using b-Lg (26
Table 1 - Test results from group A patients.
Patient
Age
years
sIgE
bLg
kU/L
SPT
PC
MWD
SPT
bLg
MWD
SPT
TgbLg
MWD
AOD
72 kDa
AOD
36 kDa
AOD
18 kDa
1 57 0.6 10 5 0 37.6 16.4 0.4
2 45 0.6 7 4 4 10.0 0.0 0.0
3 51 0.0 8 5 0 20.4 0.0 0.0
4 48 0.5 8 4 4 10.7 9.6 2.1
5 32 0.0 7 0 0 16.5 13.5 1.8
6 34 0.0 6 3 3 21.0 8.0 6.1
7 47 12.6 9 0 0 46.6 7.0 0.0
8 26 0.0 11 0 3 18.8 9.9 0.0
9 18 2.1 6 0 0 48.8 10.2 0.0
10 53 0.0 5 0 4 24.1 12.1 0.0
11 39 0.0 8 0 0 10.4 13.4 8.1
12 46 1.2 5 0 0 13.2 5.9 0.0
13 55 5.2 5 0 0 23.2 0.0 0.0
14 42 0.0 9 0 3 24.1 7.8 3.4
15 65 0.0 5 0 0 21.1 6.8 0.0
16 53 0.0 6 5 0 23.1 12.5 0.0
17 48 15.4 5 3 0 35.9 0.0 0.0
18 49 4.0 6 0 0 7.6 0.0 0.0
19 58 0.0 6 0 0 24.8 0.0 0.0
20 59 0.4 6 4 5 15.6 0.0 0.0
21 43 0.5 6 4 4 19.2 0.0 0.0
22 28 0.0 9 6 0 19.4 0.0 0.0
23 39 4.0 6 3 3 14.6 0.0 0.0
24 55 0.0 7 0 0 25.9 0.0 0.0
25 51 0.0 7 3 0 16.4 0.0 0.0
26 42 9.2 9 9 6 21.0 0.0 0.0
27 52 1.8 8 5 5 24.3 12.2 12.5
28 36 0.0 8 3 3 10.5 9.2 0.0
29 22 0.0 7 4 0 7.1 0.0 0.0
30 41 1.2 7 6 3 12.0 0.0 0.0
31 56 0.0 7 6 4 12.2 12.2 12.5
32 58 0.0 4 0 4 17.0 0.0 0.0
33 56 0.0 8 4 0 19.9 0.0 0.0
34 29 0.0 6 4 4 10.9 0.0 0.0
35 44 0.4 7 0 0 9.8 0.0 0.0
36 48 0.0 6 5 3 20.4 0.0 0.0
37 70 0.0 7 4 0 8.2 0.0 0.0
38 64 4.6 5 0 0 10.0 0.0 0.0
39 40 1.2 0 0 0 11.7 5.8 4.4
40 61 0.0 7 4 0 14.6 0.0 0.0
41 50 3.8 10 6 4 5.5 5.4 0.0
42 63 0.0 8 6 0 5.0 0.0 7.3
43 23 0.0 6 5 5 14.1 0.0 0.0
44 46 0.0 8 0 0 6.0 3.5 13.9
45 38 0.0 7 0 0 7.2 0.0 0.0
s-IgE bLg: specific IgE antibodies against beta-lactoglobulin measured by ImmunoCAP (kU/L); SPT: skin prick test; PC: positive control (histamine); MWD:
mean wheal diameter (mm); bLg: native beta-lactoglobulin; TgbLg: beta-lactoglobulin polymerized by transglutaminase and cysteine; AOD: adjusted
optical density.
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positives) for the 45 patients with positive immunoblots
via chi-squared (a,0.05 and p = 0.39) and Fisher exact
tests (a,0.05 and p = 0.46) failed to reveal significant
differences.
Combined categorical analytical sensitivity
Combined SPTs with b-Lg and TgPolb-Lg exhibited
cutaneous reactivity in 30 patients (sensitivity = 66.6%).
The combination of ImmunoCAP and SPT assays for b-Lg
revealed reactivity in 34 patients (sensitivity = 75.5%). A
combination of the three tests detected cutaneous reactivity
in 38 patients (sensitivity = 84.4%).
Immunoblot assays
Figure 1 shows the purified beta-lactoglobulin electro-
blotted 0.45-mm pore-size nitrocellulose membranes after
incubation with patient’s serum, primary antibody (goat
IgG anti-human IgE), secondary antibody (HRP-conjugated
rabbit anti-goat IgG) and DAB revelation from subjects of
group A. Our immunoblot analysis revealed 18-kDa bands
(b-Lg monomers) in 11 patients (24.4%) with a mean AOD of
1.6 (CI: 0.5 to 2.7). The immunoblots also revealed 36-kDa
bands (b-Lg dimers) in 19 patients (42.2%) with a mean
AOD of 4.0 (CI: 2.4 to 5.6). Additionally, there were bands at
72-kDa (b-Lg tetramers) in 45 patients (100%) with a mean
AOD of 17.7 (CI: 14.73 to 20.6). The mean of the difference
between the AODs of the 18-kDa bands and 36-kDa bands
was 2.4 (p= 0.00027, CI: 0.8 to 3.9). The mean of the
differences between the AODs of the 18-kDa bands and
72-kDa bands was 16.0 (p,0.0001, CI: 12.7 to 19.4). The
mean of the difference between the AODs of the 36-kDa
bands and 72-kDa bands was 13.6 (p,0.0001, CI: 10.7 to
16.5). The blot membranes incubated with the serum
subjected to BSA competition did not exhibit any difference
compared with those incubated with the corresponding
serum not subjected to BSA competition (see Figure 2). Of
the 20 patients from group B, representing milk-tolerant
controls with non-reactive SPTs for b-Lg and TgPolb-Lg and
absent b s-IgE based on ImmunoCAP, only one patient (5%)
exhibited a 72-kDa band with an AOD = 10.5 (see Figure 3).
Figure 1 - Purified beta-lactoglobulin electroblotted on 0.45-mm pore-size nitrocellulose membranes after incubation with patient’s
serum, primary antibody (goat IgG anti-human IgE), secondary antibody (HRP-conjugated rabbit anti-goat IgG) and DAB revelation,
demonstrating bands of s-IgE against b-lactoglobulin at 72 kDa (b-Lg tetramers), 36 kDa (b-Lg dimers) and 18 kDa (b-Lg monomers)
from patients in group A. Lane P=pre-stained 10-170 kDa molecular mass protein ladder (PageRulerH, Fermentas).
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Leukocyte adherence inhibition tests
In group C, the mean leukocyte adherence inhibition
(LAI) produced by ex vivo challenge with b-Lg was 39.6%
(SD: 36.8%; CI: 29.0% to 50.2%), whereas the LAI produced
by ex vivo challenge with TgPolb-Lg was 47.7 (SD: 38.4; CI:
36.6 to 58.7). The difference of the means based on a paired
t-test was not significant (p= 0.07). The correlation between
challenges was significant (Spearman r = 0.65 CI = 0.44 to
0.79 p,0.0001). Results are presented in Table 1. Figure 4
depicts the microscope aspect before and after the PBS wash
of two patients with LAI = 54% and 100%, respectively, and
a control (without antigen challenge) with 100% leukocyte
adherence.
DISCUSSION
Among the immunoreactive proteins found in whey in
bovine milk, b-Lg is prominent because of its relatively high
concentration (3 to 4 g/L on average) and low digestibility
(35). The high incidence of sensitization to this protein (38)
is understandable in light of the fact that b-Lg is not a
component of human breast milk (36) and is usually
absorbed in an unchanged form (37). b-Lg proteins naturally
occur as dimers at a pH.3 (39). Heating b-Lg to 70 C˚
induces further polymerization (40). Purified heated b-Lg
preparations generally contain monomers, dimers and
tetramers when examined using reducing SDS-PAGE (33).
Protein polymerization using TG in industrialized dairy
products is a commonly employed technique to decrease
whey syneresis and improve the gel strength/viscosity of
set-type yogurt and curd cheese (41). Treatment with TG has
been shown to decrease wheat allergenicity (42). Given the
evidence that polymerization reduces the antigenicity of b-
Lg (18) and ovalbumin in mice (43), the application of
polymerization techniques could potentially reduce the
allergenicity of industrialized foods for humans and might
be useful in producing ‘‘allergoids’’ for desensitization
immunotherapy (7). A probable explanation for this
reduced allergenicity is that polymerization masks IgE
antibody binding sites due to crosslinking of the protein.
Polymerization may also create new epitopes, which may
result in the development of hypersensitivities that are not
related to the native protein.
The skin test results presented in this study indicated a
significant reduction in the allergenicity of TgPolb-Lg
Figure 2 - Purified beta-lactoglobulin electroblotted on 0.45-mm
pore-size nitrocellulose membranes after incubation with
patient’s serum, primary antibody (goat IgG anti-human IgE),
secondary antibody (HRP-conjugated rabbit anti-goat IgG) and
DAB revelation. Immunoblot membranes exhibited bands of s-
IgE against b-lactoglobulin (b-Lg). Lane 1: Molecular weight
ladder (10 to 170 kDa); Lane 2: distinct band at 72 kDa in a
patient from group A; and Lane 3: distinct band at 72 kDa from
the same patient after ex vivo serum competition with BSA.
Figure 3 - Purified beta-lactoglobulin electroblotted on 0.45-mm
pore-size nitrocellulose membranes after incubation with
patient’s serum, primary antibody (goat IgG anti-human IgE),
secondary antibody (HRP-conjugated rabbit anti-goat IgG) and
DAB revelation. Immunoblot membranes exhibiting bands of s-
IgE against b-lactoglobulin from four non-reactive patients in
group B (Bn), from the single reactive patient from group B (Br),
and from one reactive patient from group A (A) used as a control
for the blotting technique. P =pre-stained 10-170 kDa molecular
mass protein ladder (PageRulerH, Fermentas).
Figure 4 - Leukocyte adherence inhibition tests from two
patients in group C before and after washing. Patient A
exhibited leukocyte adherence inhibition (LAI) = 100%. Patient
B exhibited leukocyte adherence inhibition (LAI) = 54%.
C = Control (without antigen) with leukocyte adherence
(LA) = 100%.
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compared with native b-Lg. Polymerization changes the
spatial distribution of allergenic epitopes, which may
explain the decreased cutaneous reactivity of these epitopes.
However, although the average skin reactivity to TgPolb-Lg
was lower than the average reactivity to b-Lg, four patients
exhibited no skin reaction to b-Lg but did exhibit significant
skin reactivity to TgPolb-Lg. This finding indicates that
transglutaminase polymerization may be deleterious for
certain patients. Polymerization also increases the analytical
detection of bs-IgE antibodies by SDS-PAGE immunoblot-
ting. Before subjecting b-Lg samples to SDS-PAGE, the
samples were heated for 10 min at 96 C˚. Heating stimulates
the polymerization of b-Lg and results in the detection of 72-
kDa bands (tetramers) (33). Because b-Lg monomers are
small proteins, they can be lost during the blotting process
due to diffusion through the nitrocellulose membrane pores.
Polymerization increases the molecular size of the protein,
which results in greater membrane retention and better
detection by specific antibodies. This effect was demon-
strated by the significant increase in the number of 72-kDa
bands compared with the number of 36-kDa and 18-kDa
bands following polymerization. Polymerization also pro-
duced a significant increase in the AOD of the 72-kDa
bands. As a secondary objective, we used immunoblotting
as a proxy for sensitization to study the accuracy of the SPTs
and ImmunoCAP tests. Both tests were unable to detect a
significant number of sensitized patients. The ImmunoCAP
test demonstrated a false-negative rate of 57.8%, and the
SPT demonstrated a false-negative rate of 42.3%. When the
assays were combined, the false-negative rate decreased to
24.5%. These data demonstrate that these two analytical
tests are complementary tools for diagnosing allergic
sensitization, and a negative result from one assay does
not necessarily indicate an absence of sensitization.
Failure of leukocytes to adhere to glass after ex vivo
challenge with specific antigens depends mostly on cellular
mechanisms resulting from the interactions of T cells, B cells
and macrophages (44-46). When activated in the presence of
a specific antigen, E-rosette-forming cells release soluble
supernatants that interfere with the glass adherence
phenomenon observed in control, unchallenged plasma
(27). The involvement of T cells was also suggested by the
fact that anti-h (anti-theta) antibodies abolish the inhibition
of adherence (47). Anti-h antibodies are specifically directed
against the C3H antigen associated with T cells (48).
Leukotrienes, specifically LTC4 (49), are important factors
in the process and are modulated by interferon secretion
(50). As cysteinyl leukotriene generation by dendritic cells is
a recognized step in the Dectin-2 recognition of allergens
(51), the LAIT may be used to analyze this pathway
indirectly.
The evaluation of cell-mediated immunoreactivity may
allow the prediction of the overall ability of an allergoid to
induce tolerance, but this subject remains an object of study.
The actual generators of tolerance are the tolerogenic
dendritic cells that prime naive T cells to become IL-10- and
TGF-b1-releasing Treg cells (52,53). Dendritic cells collect
macromolecules from mucosal layers via transepithelial
dendritic phagocytosis (54). Oral dendritic cells (oral
Langerhans cells, oLC) constitutively express high levels of
high affinity IgE receptors (FceRI) occupied by IgE antibodies
that appear to be essential for the collection of antigens (55).
The increase in molecular weight induced by enzymatic
polymerization may theoretically promote phagocytosis and
interfere with the absorption of b-Lg monomers by lipocalin
receptors (56). Thus, the ability of IgE to bind an allergoid is
essential and must be evaluated before the application of
a tolerance-induction protocol in clinical trials. Trans-
glutaminase may also be used to create covalent linkages
between different proteins. Recombinant fusion of allergenic
proteins and bacterial immunogenic proteins stimulates
dendritic cell activity (57). This fusion ability of transgluta-
minase may theoretically be used to increase the tolerogenic
activity of allergoid polymers through covalent addition of
coadjuvants. This topic warrants further study.
Additionally, the perception that cow’s milk proteins
such as beta-lactoglobulin may be immunogenic should
stimulate the creation of human milk banks to feed
premature newborns with immature digestive and immune
systems (58).
In conclusion, our data support the concept that enzy-
matic polymerization is a tool that can decrease the in vivo
allergenicity of b-Lg. As polymerization did not decrease
the in vitro humoral or ex vivo cell-mediated immunoreac-
tivity of b-Lg, we conclude that inducing polymerization by
transglutaminase represents a promising technique to
produce suitable molecules for the purpose of designing
oral/sublingual tolerance induction protocols for the treat-
ment of allergies.
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